Akero Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AKRO Nasdaq 2830 akerotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akero Therapeutics, Inc.

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD - Jan 13th, 2025 12:00 pm
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 12:00 pm
Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Dec 4th, 2024 5:59 pm
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference - Nov 26th, 2024 12:00 pm
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 - Nov 15th, 2024 4:00 pm
Akero Therapeutics to Present at the Jefferies London Healthcare Conference - Nov 13th, 2024 9:05 pm
Akero Therapeutics Advances in MASH Treatment Trials - Nov 13th, 2024 4:00 am
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 8th, 2024 12:00 pm
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Nov 2nd, 2024 4:00 pm
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - Oct 21st, 2024 11:00 am
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin - Oct 16th, 2024 12:44 pm
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds - Oct 15th, 2024 10:10 pm
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference - Sep 30th, 2024 11:00 am
Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc - Sep 12th, 2024 5:12 am
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH - Sep 9th, 2024 11:00 am
Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now - Sep 5th, 2024 4:02 am
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - Aug 28th, 2024 8:05 pm
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated - Aug 9th, 2024 2:31 pm
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down - Aug 9th, 2024 2:19 pm
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Aug 9th, 2024 11:00 am